Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agrawal, S.
Right arrow Articles by Coit, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agrawal, S.
Right arrow Articles by Coit, D. G.

Annals of Surgical Oncology, Vol 6, Issue 4 336-344, Copyright © 1999 by Society of Surgical Oncology


ARTICLES

Surgery for melanoma metastatic to the gastrointestinal tract

S. Agrawal, T. J. Yao and D. G. Coit
Department of Surgery, Columbia University College of Physicians and Surgeons, New York, New York, USA.

BACKGROUND: Gastrointestinal (GI) metastasis from melanoma has a dismal prognosis with few long-term survivors. We evaluated the role of operative intervention for melanoma metastases to the GI tract and attempted to identify prognostic factors to improve selection of patients for surgery. METHODS: Between 1977 and 1997, 68 of the 7965 patients with melanoma admitted to Memorial Sloan-Kettering Cancer Center underwent surgical exploration for melanoma metastatic to the GI tract. Characteristics of the primary tumor, regional lymph nodes, and metastatic pattern were reviewed. Data concerning the presenting signs and symptoms, laboratory values, operative findings, extent of surgical resection, recurrence pattern, and survival were analyzed. RESULTS: The most common presenting clinical features included anemia (n = 41; 60%) or abdominal pain (n = 40; 59%). The most frequently involved portion of the GI tract was the small bowel (n = 62; 91%), and the most common operative procedure was small bowel resection (n = 54; 79%). Postoperative mortality and morbidity were 2.9% (n = 2) and 8.8% (n = 6), respectively. Presenting symptoms were relieved in 90% of patients (n = 61). Median survival for all 68 patients following operative intervention was 8.2 months, with 18% survival at 5 years. By multivariate analysis, complete resection rendering the patient free of all identifiable disease (n = 19, median survival 14.9 months, 38% survival at 5 years) and a low preoperative serum lactate dehydrogenase (LDH) (n = 28, median survival 13.6 months, 35% survival at 5 years) were identified as independent favorable prognostic factors for survival. CONCLUSIONS: Operative intervention for melanoma metastatic to the GI tract is recommended for palliative reasons and can be performed with low morbidity and mortality. It is associated with prolonged survival in patients rendered free of all identifiable disease following surgical resection and in those with a low preoperative serum LDH.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
F. F. Amersi, A. M. Terando, Y. Goto, R. A. Scolyer, J. F. Thompson, A. N. Tran, M. B. Faries, D. L. Morton, and D. S.B. Hoon
Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine
Clin. Cancer Res., February 1, 2008; 14(3): 638 - 645.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
P. J. Allen and D. G. Coit
The Surgical Management of Metastatic Melanoma
Ann. Surg. Oncol., October 1, 2002; 9(8): 762 - 770.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. F. Wood, L. A. DiFronzo, D. M. Rose, P. I. Haigh, S. L. Stern, L. Wanek, R. Essner, and D. L. Morton
Does Complete Resection of Melanoma Metastatic to Solid Intra-Abdominal Organs Improve Survival?
Ann. Surg. Oncol., September 1, 2001; 8(8): 658 - 662.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society of Surgical Oncology.